

# Landsteiner-Wiener Blood Group System

## Number of antigens 3

High prevalence LW<sup>a</sup>, LW<sup>ab</sup>  
 Low prevalence LW<sup>b</sup>

## Terminology

ISBT symbol (number) LW (016)  
 CD number CD242  
 History Anti-LW, or “anti-Rh” as it was called, was produced in 1940. However, the phenotypic relationship between LW and the RhD antigen delayed recognition that LW was an independent blood group system until 1963, when it was named to honor Landsteiner and Wiener who made anti-LW in rabbits and guinea pigs after immunizing them with blood from *Macacus rhesus*. In 1982, it became a three-antigen system. The LW<sub>1</sub>, LW<sub>2</sub>, LW<sub>3</sub>, and LW<sub>4</sub> terminology was changed when it was realized that anti-Ne<sup>a</sup> (now called anti-LW<sup>b</sup>) detects an antigen antithetical to that recognized by anti-LW made by LW<sub>3</sub> people (now called anti-LW<sup>a</sup>)<sup>1</sup>.

## Expression

Tissues May be found in placenta

## Gene<sup>2</sup>

Chromosome 19p13.2  
 Name *LW (ICAM4, CD242)*  
 Organization 3 exons distributed over 2.6 kbp of gDNA  
 Product LW glycoprotein, ICAM-4



### Database accession numbers

GenBank X93093 (gene), NM\_001544 (mRNA), S78852  
 Entrez Gene ID 3386

### Molecular basis of Landsteiner-Wiener phenotypes

The reference allele, *LW\*05* or *LW\*A* (Accession number S78852), encodes *LW<sup>a</sup>* (*LW5*), *LW6*. Nucleotide differences from this reference allele, and amino acids affected, are given.

| Allele encodes                    | Allele name                 | Exon | Nucleotide | Restriction enzyme | Amino acid <sup>†</sup> | Ethnicity (prevalence)  |
|-----------------------------------|-----------------------------|------|------------|--------------------|-------------------------|---|
| <i>LW(a-b+)</i> or <i>LW:-5,7</i> | <i>LW*07</i> or <i>LW*B</i> | 1    | 299A>G     | <i>PvuII</i> –     | Gln100 Arg              | Estonians> Finns> Latvians> Lithuanians> Poles> Russians (Several), Others (Rare) |

<sup>†</sup>Change from historical counting of #1 as Ala of the mature membrane-bound protein to #1, as Met results in all amino acid numbers being increased by 30. Thus, the *LW5/LW7* polymorphism used to be amino acid number 70 and is now 100.

### Molecular basis of silencing of *LW*

Homozygosity leads to *LW<sub>null</sub>* [*LW:-5,-6,-7*; *LW(a-b-)*] phenotype. Nucleotide changes from *LW\*05* reference allele (Accession number S78852), and amino acids affected, are given.

| Allele name      | Exon | Nucleotide | Amino acid <sup>†</sup> | Ethnicity (prevalence) |
|------------------|------|------------|-------------------------|------------------------|
| <i>LW*05N.01</i> | 1    | 346–355del | 116del;fs,118Stop       | Canadian (Rare)        |

<sup>†</sup>Change from historical counting of #1 as Ala of the mature (membrane-bound protein) results in all amino acid numbers increasing by 30.

Molecular basis of weak LW antigens

*KLF1* encodes erythroid Krüppel-like factor (EKLF). Several nucleotide changes in this gene are responsible for the dominant Lu(a–b–) phenotype encoded by *In(Lu)* (see Lutheran blood group system)<sup>3,4</sup>. *KLF1* has 3 exons; the initiation codon is in exon 1 and the stop codon is in exon 3. GenBank accession numbers are U37106 (gene) and NM\_006563 (mRNA). Nucleotide difference from the *KLF1\*01* reference allele (Accession number NM\_006563), and amino acid affected, are given.

| Allele name       | Exon | Nucleotide | Amino acid | Ethnicity (prevalence) |
|-------------------|------|------------|------------|------------------------|
| <i>KLF1*BGM10</i> | 3    | 973G>A^    | Glu325Lys  | (Rare)                 |

^ = Heterozygosity for this change caused dyserythropoietic anemia and suppression of CO, IN, and LW antigens<sup>5,6</sup>.


Amino acid sequence

|             |               |       |      |         |      |          |       |        |      |        |     |     |
|-------------|---------------|-------|------|---------|------|----------|-------|--------|------|--------|-----|-----|
| MGS         | LFP           | LSLL  | FFL  | AAAYPGV | GSAL | GRRTKR   | AQSP  | KGSPLA | PSG  | TSVP   | FWV | 50  |
| RMS         | PEF           | VAVQ  | PGKS | VQLNCS  | NSCP | QPQNSS   | LRTPL | RQGKT  | LRGP | GWVS   | YQ  | 100 |
| LLD         | VR            | AWSSL | AHCL | VTCAGK  | TRW  | ATSRITA  | YKPP  | HSVILE | PPVL | KGRKY  | T   | 150 |
| LRCH        | V             | TQVFP | VGYL | VVTLRH  | GS   | RVIYSESL | ERFT  | GLDLAN | VTL  | TYEFA  | AAG | 200 |
| PRDF        | WQ            | PVIC  | HARL | NLDGLV  | VR   | NSAPITL  | MLAW  | SPAPTA | LASG | SIAALV |     | 250 |
| <u>GILL</u> | <u>TVGAAY</u> |       | LCKC | LAMK    | SQ   | A        |       |        |      |        |     | 271 |

*LW* encodes a signal peptide of 30 amino acids.

Carrier molecule<sup>7</sup>

A single pass type I membrane glycoprotein with two IgSF domains. A secreted form also has been described<sup>8</sup>.



|                   |   |
|-------------------|---|
| $M_r$ (SDS-PAGE)  | 37,000–43,000                                     |
| CHO: N-glycan     | 4 potential sites at residue 68, 78, 190, and 223 |
| CHO: O-glycan     | Present   |
| Cysteine residues | 3 pairs at residues 69/113, 73/117, and 153/210   |
| Copies per RBC    | D+ 4,400 (Adult); 5,100 (cord)                    |
|                   | D– 2,800 (Adult); 3,600 (cord)                    |

## Function

The LW glycoprotein is an intercellular adhesion molecule (ICAM-4), and a ligand for integrins. LW has 30% sequence identity with other ICAMs. ICAM-4 binds to  $\beta_2$  integrins including the LFA-1 and Mac-1 leukocyte integrins and VLA-4 ( $\alpha_4\beta_1$ ) in haemopoietic tissue and also  $\alpha_v\beta_1$ ,  $\alpha_v\beta_5$ , and maybe  $\alpha_v\beta_3$ <sup>9,10</sup>. Possible marker for lymphocyte maturation or differentiation. May assist in stabilizing erythroblastic islands during erythropoiesis<sup>11</sup>. May be involved in removal of senescent RBCs<sup>7</sup>.

## Disease association

LW antigens may be depressed during pregnancy and in some diseases, e.g., Hodgkin's disease, lymphoma, leukemia, and sarcoma<sup>7</sup>. Autoanti-LW is common in patients with warm AIHA.

Expression of ICAM-4 is elevated on sickle RBCs, and interaction between ICAM-4 and vascular endothelial cells may be involved in microvascular occlusions during painful crises of SCD<sup>12</sup>.

Phenotypes (% occurrence)

| Phenotype   | Europeans | Finns |
|---|-----------|-------|
| LW(a+b-)  | 97        | 93.9  |
| LW(a+b+)  | 3         | 6     |
| LW(a-b+)  | Rare      | 0.1   |
| Null: LW(a-b-); Rh <sub>null</sub> RBCs type LW(a-b-) although LW is normal |           |       |

There is a phenotypic relationship between LW and D antigens: in adults, D- RBCs have lower expression of LW antigens than D+ RBCs (ratio 1:1.5). In cord RBCs, LW is strongly expressed in D- and D+ RBCs.

Obsolete compared to current phenotype names

| Obsolete                | Obsolete        | Current              |
|-------------------------|-----------------|----------------------|
| LW+, D+                 | LW <sub>1</sub> | LW(a+b-) or LW(a+b+) |
| LW+, D-                 | LW <sub>2</sub> | LW(a+b-) or LW(a+b+) |
| LW-, D+ or D-           | LW <sub>3</sub> | LW(a-b+)             |
| LW-, D+ or D-           | LW <sub>4</sub> | LW(a-b-)             |
| LW-, Rh <sub>null</sub> | LW <sub>0</sub> | LW(a-b-)             |

Comments

LW antigens require intramolecular disulfide bonds and the presence of divalent cations, notably Mg<sup>2+</sup>, for expression<sup>13</sup>.

References

<sup>1</sup> Sistonen, P., Tippet, P., 1982. A “new” allele giving further insight into the LW blood group system. Vox Sang 42, 252–255.

<sup>2</sup> Hermand, P., et al., 1996. Characterization of the gene encoding the human LW blood group protein in LW<sup>+</sup> and LW<sup>-</sup> phenotypes. Blood 87, 2962–2967.

- <sup>3</sup> Singleton, B.K., et al., 2009. A novel GATA-1 mutation (Ter414Arg) in a family with the rare X-linked blood group Lu(a-b-) phenotype [abstract]. *Blood* 114, 783.
- <sup>4</sup> Singleton, B.K., et al., 2008. Mutations in EKLF/KLF1 form the molecular basis of the rare blood group In(Lu) phenotype. *Blood* 112, 2081–2088.
- <sup>5</sup> Arnaud, L., et al., 2010. A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. *Am J Hum Genet* 87, 721–727.
- <sup>6</sup> Parsons, S.F., et al., 1994. A novel form of congenital dyserythropoietic anemia associated with deficiency of erythroid CD44 and a unique blood group phenotype [In(a-b-), Co(a-b-)]. *Blood* 83, 860–868.
- <sup>7</sup> Parsons, S.F., et al., 1999. Erythroid cell adhesion molecules Lutheran and LW in health and disease. *Baillieres Clin Haematol* 12, 729–745.
- <sup>8</sup> Lee, G., et al., 2003. Novel secreted isoform of adhesion molecule ICAM-4: potential regulator of membrane-associated ICAM-4 interactions. *Blood* 101, 1790–1797.
- <sup>9</sup> Bailly, P., et al., 1995. The red cell LW blood group protein is an intercellular adhesion molecule which binds to CD11/CD18 leukocyte integrins. *Eur J Immunol* 25, 3316–3320.
- <sup>10</sup> Spring, F.A., et al., 2001. Intercellular adhesion molecule-4 binds  $\alpha_4\beta_1$  and  $\alpha_v$ -family integrins through novel integrin-binding mechanisms. *Blood* 98, 458–466.
- <sup>11</sup> Chasis, J.A., Mohandas, N., 2008. Erythroblastic islands: Niches for erythropoiesis. *Blood* 112, 470–478.
- <sup>12</sup> Zennadi, R., et al., 2004. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alpha v beta 3 interactions. *Blood* 104, 3774–3781.
- <sup>13</sup> Bloy, C., et al., 1990. Surface orientation and antigen properties of Rh and LW polypeptides of the human erythrocyte membrane. *J Biol Chem* 265, 21482–21487.

## LW<sup>a</sup> Antigen

### Terminology

|                      |  |
|----------------------|--|
| ISBT symbol (number) | LW5 (016005 or 16.5)   |
| Obsolete names       | LW; LW <sub>1</sub> ; LW <sub>2</sub>  |
| History              | Named LW <sup>a</sup> in 1982 when the antithetical relationship to Ne <sup>a</sup> (LW <sup>b</sup> ) was recognized. At that time, the antigen names LW1 to LW4 were not used, because they had been used to designate phenotypes. |

### Occurrence

|                 |      |
|-----------------|------|
| All populations | 100% |
|-----------------|------|

### Antithetical antigen

LW<sup>b</sup> (LW7)

### Expression

|           |  |
|-----------|--|
| Cord RBCs | Well expressed on D+ and D–  |
| Altered   | Weak on D– RBCs from adults<br>Weak or absent on RBCs stored in EDTA |

Molecular basis associated with LW<sup>a</sup> antigen<sup>1</sup>

|            |                                    |
|------------|------------------------------------|
| Amino acid | Gln100 (previously reported as 70) |
| Nucleotide | A at bp 299 in exon 1              |

Effect of enzymes and chemicals on LW<sup>a</sup> antigen on intact RBCs

|                  |  |
|------------------|--|
| Ficin/Papain     | Resistant  |
| Trypsin          | Resistant  |
| α-Chymotrypsin   | May be weakened  |
| Pronase          | Sensitive  |
| DTT 200 mM/50 mM | Sensitive/sensitive (thus sensitive to WARM™ and ZZAP) |
| Acid             | Resistant  |

In vitro characteristics of alloanti-LW<sup>a</sup>

|                      |                    |
|----------------------|--------------------|
| Immunoglobulin class | IgG (usually); IgM |
| Optimal technique    | IAT or RT          |

Clinical significance of alloanti-LW<sup>a</sup>

|                      |   |
|----------------------|---|
| Transfusion reaction | No to mild/delayed [Rare; D–, LW(a+) RBCs survive well] |
| HDFN                 | No to mild (very rare)                                  |

Autoanti-LW<sup>a</sup>

Autoanti-LW<sup>a</sup> with suppression of LW antigens has been reported. Sometimes observed in plasma of patients with warm AIHA.

Comments

Testing pronase or DTT treated D+ RBCs is a useful way to differentiate anti-D from anti-LW; anti-D will be reactive while anti-LW will not. Siblings of patients with alloanti-LW<sup>a</sup> should be tested for compatibility, and the patient urged to donate blood for cryogenic storage when his/her clinical state permits, in cases where D–, LW(a+) RBCs do not survive well. Antigen expression requires Mg<sup>2+</sup> (may be weak in EDTA samples).

Reference

<sup>1</sup> Hermand, P., et al., 1995. Molecular basis and expression of the LW<sup>a</sup>/LW<sup>b</sup> blood group polymorphism. Blood 86, 1590–1594.

## LW<sup>ab</sup> Antigen

### Terminology

|                      |  |
|----------------------|--|
| ISBT symbol (number) | LW6 (016006 or 16.6)   |
| Obsolete names       | Bigelow; Big; LW; LW <sub>4</sub>  |
| History              | LW <sub>4</sub> was renamed LW <sup>ab</sup> when the LW blood group system was established in 1982. |

### Occurrence

|                 |      |
|-----------------|------|
| All populations | 100% |
|-----------------|------|

### Expression

|           |  |
|-----------|--|
| Cord RBCs | Well expressed on D+ and D–  |
| Altered   | Weak on D– RBCs from adults<br>Weak or absent on RBCs stored in EDTA |

### Molecular basis associated with LW<sup>ab</sup> antigen

See System pages for molecular basis of LW(a–b–) phenotype.

### Effect of enzymes and chemicals on LW<sup>ab</sup> antigen on intact RBCs

|                  |  |
|------------------|--|
| Ficin/Papain     | Resistant  |
| Trypsin          | Resistant  |
| α-Chymotrypsin   | May be weakened  |
| Pronase          | Sensitive  |
| DTT 200 mM/50 mM | Sensitive/sensitive (thus sensitive to WARM™ and ZZAP) |
| Acid             | Resistant  |

### *In vitro* characteristics of alloanti-LW<sup>ab</sup>

|                      |           |
|----------------------|-----------|
| Immunoglobulin class | IgG; IgM  |
| Optimal technique    | 37°C; IAT |

### Clinical significance of alloanti-LW<sup>ab</sup>

|                      |   |
|----------------------|---|
| Transfusion reaction | No data   |
| HDFN                 | Mild; an autoanti-LW <sup>ab</sup> has been reported to cause HDFN <sup>1</sup> |

### Autoanti-LW<sup>ab</sup>

Autoanti-LW<sup>ab</sup> with suppression of LW antigens occurs<sup>2</sup>.  
Sometimes observed in plasma of patients with warm AIHA.



Comments

Siblings of patients with anti-LW<sup>ab</sup> should be tested for compatibility, and the patient urged to donate blood for cryogenic storage when his/her clinical state permits.

If random units have shortened survival, experts agree that D– RBCs are the component of choice.

Only one alloanti-LW<sup>ab</sup> has been described in an LW(a–b–) person (Bigelow). Her brother also had the LW(a–b–) phenotype.

When LW antigens are suppressed, the anti-LW<sup>ab</sup> may mimic an alloantibody and is a more common specificity than autoanti-LW<sup>a</sup>.

Antigen expression requires Mg<sup>2+</sup> (may be weak in EDTA samples).

References

<sup>1</sup> Davies, J., et al., 2009. Haemolytic disease of the foetus and newborn caused by auto anti-LW. *Transfus Med* 19, 218–219.

<sup>2</sup> Storry, J.R., 1992. Review: the LW blood group system. *Immunohematology* 8, 87–93.

LW<sup>b</sup> Antigen

Terminology

|                      |   |
|----------------------|---|
| ISBT symbol (number) | LW7 (016007 or 16.7)  |
| Obsolete names       | Ne <sup>a</sup> ; LW <sub>3</sub>   |
| History              | Name changed from Ne <sup>a</sup> when the antithetical relationship to LW <sup>a</sup> was recognized in 1982. |

Occurrence

|                          |                  |
|--------------------------|------------------|
| Most populations         | Rare             |
| Estonians                | 8%               |
| Finns                    | 6%               |
| Latvians and Lithuanians | 5%               |
| Poles and Russians       | 2%               |
| Other Europeans          | <1% <sup>1</sup> |

Antithetical antigen

LW<sup>a</sup> (LW5)

Expression

|           |                                       |
|-----------|---------------------------------------|
| Cord RBCs | Well expressed on D+ and D–           |
| Altered   | Weak on D– RBCs from adults           |
|           | Weak or absent on RBCs stored in EDTA |

## Molecular basis associated with LW<sup>b</sup> antigen<sup>2</sup>

|            |                                    |
|------------|------------------------------------|
| Amino acid | Arg100 (previously reported as 70) |
| Nucleotide | G at bp 299 in exon 1              |

## Effect of enzymes and chemicals on LW<sup>b</sup> antigen on intact RBCs

|                  |  |
|------------------|--|
| Ficin/Papain     | Resistant (enhanced)                                   |
| Trypsin          | Resistant (enhanced)                                   |
| α-Chymotrypsin   | May be weakened  |
| Pronase          | Sensitive  |
| DTT 200 mM/50 mM | Sensitive/sensitive (thus sensitive to WARM™ and ZZAP) |
| Acid             | Resistant  |

## *In vitro* characteristics of alloanti-LW<sup>b</sup>

|                      |           |
|----------------------|-----------|
| Immunoglobulin class | IgG; IgM  |
| Optimal technique    | 37°C; IAT |

## Clinical significance of alloanti-LW<sup>b</sup>

|                      |            |
|----------------------|------------|
| Transfusion reaction | No to mild |
| HDFN                 | No to mild |

## Comments

Antigen expression requires Mg<sup>2+</sup> (may be weak in EDTA samples).

## References

- <sup>1</sup> Sistonen, P., et al., 1999. The LW<sup>b</sup> blood group as a marker of prehistoric Baltic migrations and admixture. *Hum Hered* 49, 154–158.
- <sup>2</sup> Hermand, P., et al., 1995. Molecular basis and expression of the LW<sup>a</sup>/LW<sup>b</sup> blood group polymorphism. *Blood* 86, 1590–1594.